Focused On-demand Library for Polyribonucleotide nucleotidyltransferase 1, mitochondrial

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q8TCS8

UPID:
PNPT1_HUMAN

ALTERNATIVE NAMES:
3'-5' RNA exonuclease OLD35; PNPase old-35; Polynucleotide phosphorylase 1; Polynucleotide phosphorylase-like protein

ALTERNATIVE UPACC:
Q8TCS8; Q53SU0; Q68CN1; Q7Z7D1; Q8IWX1; Q96T05; Q9BRU3; Q9BVX0

BACKGROUND:
The protein Polyribonucleotide nucleotidyltransferase 1, mitochondrial, known alternatively as 3'-5' RNA exonuclease OLD35, is involved in numerous RNA metabolic processes, including RNA degradation and mitochondrial mRNA processing. It functions both in the mitochondrial intermembrane space and the cytoplasm, playing roles in mitochondrial morphogenesis, respiration, and RNA cell surveillance.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Polyribonucleotide nucleotidyltransferase 1 could open doors to potential therapeutic strategies. Its involvement in critical diseases like Combined oxidative phosphorylation deficiency 13 and Deafness, autosomal recessive, 70, underscores its potential as a therapeutic target, offering hope for treatments that could significantly impact mitochondrial and neurological health.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.